TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35720286
Drug: Sub-thrombolytic dose
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-thrombolytic dose of tPA along with ozanimod
Study: 35720286
Drug: Sub-thrombolytic dose
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-thrombolytic dose of tPA along with vehicle control
Study: 35720312
Drug: Tislelizumab plus
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab plus sequential neoadjuvant chemotherapy
Study: 35721046
Drug: Liposomal Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal Cyclosporine A for inhalation (L-CsA-i)
Study: 35721744
Drug: RJX (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: RJX (1.25 mL/kg or 2.5 mL/kg)
Study: 35722047
Drug: 12-week structured
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week structured physical activity programme during chemotherapy
Study: 35722126
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity integrated into learning (daily PA unit of 45 min over 3 years)
Study: 35722822
Drug: DS-1001 (125-1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1001 (125-1400 mg orally, twice daily)
Study: 35725143
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss before treatment
Study: 35725143
Drug: Weight stable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight stable before treatment
Study: 35725143
Drug: Weight gain
Normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight gain before treatment
Study: 35725262
Drug: Paracetamol usage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol usage
Study: 35725542
Drug: Standardized prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized prolonged discharge prescription forms plus education
Study: 35725623
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with agalsidase alfa
Study: 35725670
Drug: Serum steroid
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum steroid profiling including 21-deoxycortisol and cosyntropin stimulation test with 17OHP
Study: 35725917
Drug: Enteral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral iron supplementation (median cumulative intake 58.5 mg/kg at 28 days, 235.8 mg/kg through 36 weeks)
Study: 35725917
Drug: Parenteral iron
Normalized name: Iron, parenteral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral iron supplementation (median cumulative intake 3.1 mg/kg at 28 days, 3.56 mg/kg through 36 weeks)
Study: 35726793
Drug: Combination ipilimumab/nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ipilimumab/nivolumab followed by maintenance nivolumab
Study: 35726793
Drug: Combination ipilimumab/nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ipilimumab/nivolumab
Study: 35726971
Drug: Concentrated parenteral
Normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentrated parenteral nutrition (PN)
Study: 35726971
Drug: Original parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original parenteral nutrition (PN)
Study: 35727618
Drug: mHealth patch
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth patch device with AI arrhythmia analysis for AF detection
Study: 35727622
Drug: Digitally delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitally delivered treatment program for LBP (3 months duration)
Study: 35727633
Drug: Tumor-infiltrating lymphocytes
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor-infiltrating lymphocytes (TILs) infusion after concurrent chemoradiotherapy (CCRT) plus i.m. IL-2 injections
Study: 35728746
Drug: Biologics (including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics (including omalizumab, benralizumab, mepolizumab, dupilumab, reslizumab)
Study: 35728746
Drug: Biologics (switching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics (switching biologics)
Study: 35728746
Drug: Non-anti-immunoglobulin E
Normalized name: anti-D (rh) immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anti-immunoglobulin E biologics
Study: 35729005
Drug: Dostarlimab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dostarlimab (500 mg IV every 3 weeks for Cycles 1-4, then 1000 mg Q6W) until disease progression or unacceptable toxicity
Study: 35729429
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment strategies, invasive procedures, revascularisation therapies, and use of mechanical circulatory support devices, including extracorporeal cardiopulmonary resuscitation.
Study: 35729673
Drug: D-allulose (8.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-allulose (8.5 g consumed before iftar meal)
Study: 35731948
Drug: Pyrazinamide AUC0-24
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrazinamide AUC0-24 of 379 mg × h/L
Study: 35734087
Drug: Primary 2-dose
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary 2-dose series of COVID-19 mRNA vaccination during pregnancy
Study: 35735167
Drug: Friend-oriented networks
Normalized name: Fisherman's Friend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Friend-oriented networks with weekly contact
Study: 35737639
Drug: CC-90011 (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90011 (once per week in 28-day cycles)
Study: 35737873
Drug: Ixazomib in
Normalized name: Product containing ixazomib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib in combination with cyclophosphamide and dexamethasone
Study: 35737873
Drug: Ixazomib maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib maintenance after 12 cycles of treatment
Study: 35737873
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to alternate therapy
Study: 35738999
Drug: Trametinib 2mg
Normalized name: TRAMETINIB 2MG ORAL TAB
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib 2mg oral daily along with TAS-102 starting at 35 mg/m
Study: 35740079
Drug: Low-dose radiotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiotherapy (LDRT) 0.5 Gy
Study: 35740603
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) at 3 mg/m²
Study: 35740603
Drug: Fractionated doses
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated doses of Gemtuzumab ozogamicin (GO3)
Study: 35740603
Drug: CLAG-M (cladribine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLAG-M (cladribine, high-dose cytarabine, G-CSF, and dose-escalated mitoxantrone)
Study: 35742400
Drug: e-OTCAT program
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-OTCAT program during 12 consecutive weeks since the beginning of chemotherapy
Study: 35743360
Drug: Preoperative platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative platelet reactivity to P2Y12 inhibitors
Study: 35747193
Drug: PT-112 (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT-112 (125 mg/m)
Study: 35747402
Drug: Low plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low plasma mannose-binding lectin (p-MBL) levels (≤500 µg/l) in RPL patients
Study: 35747402
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma mannose-binding lectin (p-MBL) levels (>3000 µg/l) in RPL patients
Study: 35747402
Drug: Intermediate plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate plasma mannose-binding lectin (p-MBL) levels (501-3000 µg/l) in RPL patients
Study: 35747712
Drug: Sintilimab in
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab in combination with concurrent chemoradiotherapy (cCRT)
Study: 35747751
Drug: Oral Co-Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3
Study: 35748318
Drug: Postprandial studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postprandial studies with whole-body positron emission tomography/computed tomography (PET/CT) using oral [18F]fluoro-thia-heptadecanoic acid and dynamic PET/CT with intravenous [11C]palmitate
Study: 35748699
Drug: Fazirsiran 200
Normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazirsiran 200 mg subcutaneously on day 1 and week 4, then every 12 weeks (cohorts 1 and 2)
Study: 35748699
Drug: Fazirsiran 100
Normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazirsiran 100 mg subcutaneously on day 1 and week 4, then every 12 weeks (cohort 1b)
Study: 35748707
Drug: IV ganaxolone
Normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ganaxolone (low, 500 mg/day; medium, 650 mg/day; high, 713 mg/day)
Study: 35750354
Drug: SPL-108 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL-108 with weekly paclitaxel
Study: 35750559
Drug: No prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prior intravesical therapy
Study: 35750695
Drug: CX-5461 (G-quadruplex
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX-5461 (G-quadruplex stabilizer)
Study: 35750958
Drug: Intravenous Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Vitamin C (IVC) 1-100 g in healthy volunteers
Study: 35750958
Drug: Intravenous Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Vitamin C (IVC) 25-100 g in oncology participants
Study: 35750958
Drug: Intravenous Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Vitamin C (IVC) 100 g
Study: 35750958
Drug: Intravenous Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Vitamin C (IVC) up to 100 g
Study: 35751496
Drug: nab-paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel at 260 mg/m² combined with S-1 (80-120 mg/day, d1-14, q3w) for 6 cycles followed by 8 cycles of S-1 monotherapy
Study: 35751496
Drug: nab-paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel at 180 mg/m²
Study: 35753092
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy and statins adherence
Study: 35756891
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application for clinical monitoring of patients prescribed home oxygen therapy
Study: 35758418
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily PrEP users)
Study: 35759134
Drug: ASP1650 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP1650 (1000 mg/m)
Study: 35760939
Drug: SARS-CoV-2 vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccination (various vaccines including Gam-COVID-Vac, ChAdOx1 nCoV-19, BBIBP-CorV)
Study: 35762834
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (interferon beta-1b 16 million units daily and remdesivir 200 mg loading on day 1 followed by 100 mg daily on day 2 to 5)
Study: 35762890
Drug: Transarterial radioembolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial radioembolization (TARE) with yttrium 90, details on dosage and duration not available.
Study: 35763351
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol patches (200 µg/day) for 3 weeks postpartum
Study: 35763351
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches for 3 weeks postpartum
Study: 35763667
Drug: Involved-field radiotherapy
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved-field radiotherapy (IFRT) at a dose of 21-Gy for SERs after 3 chemotherapy cycles.
Study: 35763667
Drug: No involved-field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No involved-field radiotherapy (IFRT) for SERs after 3 chemotherapy cycles.
Study: 35763667
Drug: Involved-field radiotherapy
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved-field radiotherapy (IFRT) at a dose of 21-Gy for RERs after 3 chemotherapy cycles.
Study: 35763667
Drug: No involved-field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No involved-field radiotherapy (IFRT) for RERs after 3 chemotherapy cycles.
Study: 35764393
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of mRNA vaccine administered within 6 months after the second dose
Study: 35764393
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of mRNA vaccine
Study: 35764393
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of mRNA vaccine
Study: 35764638
Drug: Lentiviral-transduced autologous
Normalized name: Autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence
DrugBank: Atidarsagene autotemcel (DB17538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentiviral-transduced autologous hematopoietic stem cells following busulfan (6 mg/kg total) conditioning
Study: 35764637
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of BNT162b2 (BB)
Study: 35764637
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of CoronaVac (CC)
Study: 35764637
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of BNT162b2 (B)
Study: 35764637
Drug: CoronaVac (CC)
Normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac (CC)
Study: 35764637
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (BNT162b2 and CoronaVac)
Study: 35764796
Drug: Decentralized clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decentralized clinical trial (DCT) with oral anticoagulation adherence (OACA)
Study: 35764995
Drug: Survey during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey during maintenance therapy (T2)
Study: 35764995
Drug: Survey near
Normalized name: OCTINOXATE 3.5 mg in 1 mL / TITANIUM DIOXIDE 1.9 mg in 1 mL TOPICAL LIQUID [Revlon Nearly Naked Makeup]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey near treatment completion (T3)
Study: 35765145
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of donor-derived cell-free DNA (dd-cfDNA) fraction and quantity
Study: 35767123
Drug: No inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inhaled corticosteroids (ICS) treatment
Study: 35767182
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg per day)
Study: 35767182
Drug: Apatinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib combined with radioactive iodine (RAI) therapy
Study: 35767205
Drug: Sitravatinib (10-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitravatinib (10-200 mg)
Study: 35767205
Drug: Sitravatinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitravatinib (150 mg)
Study: 35767439
Drug: Oncolytic virus
Normalized name: Reovirus type 3 dearing oncolytic virus without transgenes
DrugBank: Pelareorep (DB17284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oncolytic virus DNX-2401 infusion followed by radiotherapy
Study: 35768023
Drug: CT-STAR (cone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-STAR (cone beam computed tomography-guided stereotactic adaptive radiation therapy)
Study: 35768023
Drug: nonadapted CT-guided
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: nonadapted CT-guided stereotactic body radiation therapy (SBRT)
Study: 35768164
Drug: TCR-transduced T-cell
Normalized name: Neoantigen specific TCR-T cell therapy
DrugBank: Neoantigen specific TCR-T cell therapy (DB17458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCR-transduced T-cell product (TBI-1301) with a dose of 5×10
Study: 35768859
Drug: Ziv-aflibercept 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziv-aflibercept 1.25 mg (0.05 ml) administered by intravitreal injection monthly for 6 months
Study: 35769244
Drug: Generic once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic once-daily tacrolimus
Study: 35769360
Drug: DISE-guided CPAP
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DISE-guided CPAP titration
Study: 35769360
Drug: CSC CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSC CPAP titration
Study: 35769368
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no alteplase treatment)
Study: 35771301
Drug: Aflibercept combined
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept combined with docetaxel (75 mg/m²)
Study: 35771301
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m²)
Study: 35771572
Drug: Decreased default
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreased default number of opioid doses from 30 to 12 in pediatric otolaryngology patients post-intervention.
Study: 35771573
Drug: Venlafaxine extended
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine extended release (37.5 mg to 300 mg daily for up to 12 weeks)
Study: 35771832
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TMT and video game multitask training (VGMT)
Study: 35772170
Drug: Rondoraptivon pegol
Normalized name: Rondoraptivon pegol
DrugBank: BT200 (DB18333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rondoraptivon pegol (3 mg subcutaneously on days 1, 4, and 7, followed by 6 to 9 mg weekly until day 28)
Study: 35772177
Drug: O3AEE (omega-3-acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: O3AEE (omega-3-acid ethyl esters) 2 g/day
Study: 35772417
Drug: Daily PrEP
Normalized name: Zinc Oxide 238 mg in 1 mL / Titanium Dioxide 41 mg in 1 mL TOPICAL LOTION [bareMinerals Prep Step Mineral Shield Broad Spectrum SPF 50 Daily Prep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PrEP (tenofovir disoproxil 245 mg and emtricitabine 200 mg, one pill per day)
Study: 35772417
Drug: On-demand PrEP
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand PrEP (following IPERGAY dosing recommendation)
Study: 35772429
Drug: SHR2554 (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554 (350 mg twice daily)
Study: 35772429
Drug: SHR2554 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554 (various doses)
Study: 35772429
Drug: SHR2554 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554 (all doses)
Study: 35772805
Drug: Gadolinium administration
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium administration (20 and 120 minutes)
Study: 35772852
Drug: Intraventricular enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular enzyme replacement therapy (ERT) with cerliponase alfa
Study: 35772853
Drug: sacubitril/valsartan 24/26
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan 24/26 mg twice a day
Study: 35774932
Drug: Community-based, respondent-driven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based, respondent-driven sampling (RDS) survey with HCV screening and immediate treatment
Study: 35775211
Drug: Breast cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer therapy with physical activity (PA) participation
Study: 35775211
Drug: Breast cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer therapy without physical activity (inactive)
Study: 35775211
Drug: Pre-treatment physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment physical activity scores
Study: 35775211
Drug: Post-treatment physical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment physical activity scores after three months of BC therapy
Study: 35775211
Drug: Six-minute walk
Normalized name: Tagetes minuta flower oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-minute walk distance (6MWD) pre-treatment
Study: 35775211
Drug: Six-minute walk
Normalized name: Tagetes minuta flower oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-minute walk distance (6MWD) post-treatment
Study: 35775211
Drug: Left ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left ventricular ejection fraction (LVEF) pre-treatment
Study: 35775211
Drug: Left ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left ventricular ejection fraction (LVEF) post-treatment